Non-Small-Cell Lung Cancer | Current Treatment | US | 2016

Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-defined patient populations and the FDA’s approval of several targeted therapies in 2015 have positioned NSCLC at the forefront of personalized medicine in oncology and resulted in an evolving treatment landscape for the disease. This analysis provides insight on current use of approved therapies for NSCLC in the United States and on oncologists’ perception of these therapies.

launch Related Market Assessment Reports